Kawasaki Disease and COVID-19: What Parents Need to Know

Understand the link between Kawasaki disease and COVID-19 in children, symptoms, risks, and medical guidance.

By Medha deb

Created on Sep 25, 2025

Understand the link between Kawasaki disease and COVID-19 in children, symptoms, risks, and medical guidance.

Kawasaki Disease and COVID-19: Unraveling the Connection

The COVID-19 pandemic has prompted renewed clinical attention to Kawasaki disease (KD), a rare but serious inflammatory condition in children. As reports of children with COVID-19 or exposure to the virus developing Kawasaki-like symptoms have emerged, parents and healthcare providers have sought to understand the risks, symptoms, and implications of this association. This article explores the nature of Kawasaki disease, its potential connection with coronavirus infection, symptoms to watch, and guidance on seeking care for children.

What Is Kawasaki Disease?

Kawasaki disease is an acute, self-limited vasculitis—meaning it causes inflammation of the blood vessels—predominantly affecting children under five years old, though it can occur in older children as well. First described in Japan in 1967, KD can have severe complications, notably heart issues such as coronary artery aneurysms. The overall cause of Kawasaki disease remains unknown, but specialists suspect a mix of genetic predisposition, environmental factors, and infectious agents may trigger the disease.

Understanding the intricate relationship between Kawasaki disease and COVID-19 is crucial for parents and healthcare providers. For a deeper dive into this important topic, explore our comprehensive guide on Kawasaki Disease and COVID-19: Understanding the Link in Children. This resource highlights symptoms, risks, and actionable steps to safeguard your child's health.

Typical Symptoms of Kawasaki Disease

High fever lasting more than five days (usually above 102°F or 38.9°C)
Red, bloodshot eyes without discharge (conjunctivitis)
Redness or swelling of the lips, tongue, or mouth (sometimes seen as a “strawberry tongue”)
Skin rash (often polymorphic or varied in appearance)
Swelling and redness of the hands and feet; skin peeling may occur later
Enlarged lymph nodes in the neck

Some children may display all or only some of these symptoms. Inflammation can also affect multiple organ systems, including the heart, blood vessels, skin, mucous membranes, and lymph nodes.

COVID-19 and the Surge of Kawasaki-like Illness in Children

To fully grasp the nuances of how COVID-19 impacts heart health, it’s essential to be well-informed. Discover the details in our detailed analysis of Understanding the Impact of COVID-19 on Heart Health. This resource will equip you with the knowledge needed to navigate potential risks associated with COVID-19 and its implications for pediatric patients.

During the first waves of the COVID-19 pandemic in 2020, clinicians in Europe and North America identified a surprising increase in cases of children presenting with symptoms reminiscent of Kawasaki disease. These clustered cases led to widespread concern about a possible relationship between SARS-CoV-2, the virus responsible for COVID-19, and severe inflammatory syndromes in children.

A number of global studies reported a significant spike in cases resembling Kawasaki disease about two weeks after peaks of COVID-19 community outbreaks. Such cases often exhibited more severe systemic inflammation than classic KD, frequently requiring hospitalization and, in some cases, intensive care. While classic KD is rare, this increase prompted urgent investigation and the development of updated pediatric guidelines.

It's essential to understand the overlapping symptoms and risks associated with COVID-19-related heart conditions. We recommend reading our insightful article on Pericarditis and COVID-19: Understanding Heart Inflammation Associated With Coronavirus. This piece provides critical insights into the heart's response to COVID-19 and MIS-C, equipping readers with valuable knowledge.

Kawasaki Disease and MIS-C: Overlapping Syndromes?

Some of these Kawasaki-like cases were classified as a distinct yet related syndrome called MIS-C (Multisystem Inflammatory Syndrome in Children). MIS-C features both similarities and differences compared to Kawasaki disease, including higher rates of gastrointestinal and cardiovascular involvement.

Feature	Kawasaki Disease	MIS-C
Typical Age Range	Under 5 years old	5–14 years old (but can occur at any age)
Primary Symptoms	Fever, rash, conjunctivitis, lymph node swelling, cracked lips	Fever, rash, abdominal pain, vomiting, diarrhea, heart problems
Cardiac Involvement	Coronary artery aneurysms	More likely to have heart dysfunction, low blood pressure/shock
Link to COVID-19	Suspected trigger in some cases during pandemic	Strong epidemiological association, post-infection immune response

How Might COVID-19 Trigger Kawasaki Disease?

The exact mechanisms remain unclear, but several theories suggest that viral respiratory infections can initiate immune dysregulation in some genetically predisposed children. SARS-CoV-2 may act as one such infectious “trigger,” leading to an abnormal and sustained inflammatory reaction impacting various organ systems. This concept aligns with historical evidence linking KD outbreaks to respiratory viral epidemics, such as previous influenza pandemics.

Understanding the differential diagnosis of respiratory symptoms is crucial for caregivers. For a clearer perspective, check out our guide comparing symptoms in Croup vs. COVID-19 in Children: Symptoms, Differences, and Care. This resource can help parents differentiate between conditions that show similar signs and ensure timely medical responses.

During COVID-19 surges, hospitals observed that children presenting with Kawasaki-like symptoms often tested positive for SARS-CoV-2 by PCR or antibody testing, or had known COVID-19 exposures within the previous 1–8 weeks. Epidemiological studies from France, Italy, the UK, and the U.S. reinforce this link, although not every child with KD symptoms is confirmed to have had COVID-19.

Recognizing Symptoms: When to Seek Immediate Care

Timely recognition of Kawasaki disease or MIS-C is critical because early intervention can significantly reduce the risk of severe complications, particularly to the heart. Parents and caregivers should seek medical care promptly if a child presents with any of the following:

Awareness of pediatric heart disease is essential for early detection and intervention. To learn more about this important issue, visit our resource on Heart Disease in Children: Types, Symptoms, Causes, and Care. This guide provides valuable information that can help caregivers recognize early warning signs and seek timely medical help.

Persistent fever (over five days) not relieved with usual fever reducers
Red eyes, mouth, tongue, or skin rash
Swelling or redness of hands and feet
Unusual lethargy, fussiness, or irritability
Swollen lymph nodes (especially in the neck)
Symptoms such as severe abdominal pain, vomiting, diarrhea, or difficulty breathing (especially if occurring alongside fever and rash)

If a child develops chest pain, difficulty breathing, confusion, or signs of poor circulation (pale, cold, or blue-tinged skin), immediate emergency care is needed.

Diagnosis of Kawasaki Disease and Related Syndromes

Diagnosis is based primarily on clinical symptoms and the exclusion of other possible causes. Healthcare providers may order the following tests:

When dealing with cardiovascular symptoms in children, it's crucial to be informed about myocarditis. Our article on Myocarditis: Symptoms, Causes, Diagnosis, and Treatment provides vital insights into this condition, helping parents understand treatment options and recognize symptoms that warrant immediate attention.

Blood tests: to check for inflammation, organ function, and rule out infections
COVID-19 testing: via PCR or serology (antibody test)
Echocardiogram: to detect possible coronary artery involvement or heart inflammation
Other imaging as indicated (e.g., chest X-ray, abdominal ultrasound)

Children with classical Kawasaki disease and those with features of MIS-C may be managed with similar initial investigations, but those with suspected COVID-19 exposure or positive test results are particularly scrutinized for more severe organ involvement.

Treatment: What Are the Options?

The cornerstone of treatment for Kawasaki disease has historically been high-dose intravenous immunoglobulin (IVIG) therapy and aspirin. This approach lowers the risk of coronary artery complications and often results in rapid improvement. Other interventions may include:

Antipyretics and anti-inflammatory medications to reduce fever and inflammation
Corticosteroids in severe or refractory cases
Supportive care for organ involvement (e.g., IV fluids, cardiac support, respiratory support)

Children with MIS-C or Kawasaki-like disease during COVID-19 may require intensive care support if multiple organs are involved. Early studies have raised concerns about increased rates of IVIG resistance in children who developed KD within weeks after COVID-19 infection.

Current Understanding and Ongoing Research

While a clear association has been observed between COVID-19 outbreaks and increases in Kawasaki disease and MIS-C cases, researchers emphasize that most children infected with SARS-CoV-2 do not develop severe illness or inflammatory syndromes. Nonetheless, awareness and early recognition remain essential.

Key facts:

Incidence of Kawasaki-like disease peaked two weeks after COVID-19 infection surges in several regions.
Cases have been reported worldwide, notably in Europe, the UK, the US, and Africa.
Boys and children of African, Caribbean, and South Asian ancestry may have higher risk.
The definite cause for increased cases with COVID-19 remains under intense investigation.
COVID-19-associated KD and MIS-C are rare compared to the total number of child COVID-19 cases, but may be more severe.
IVIG shortage could become an issue in regions experiencing surges of both MIS-C and COVID-19.

What Should Parents and Caregivers Do?

Monitor children with fever for at least 3–5 days—especially if unresponsive to standard treatment.
Take note of any additional symptoms such as rashes, red eyes, or swollen extremities.
If concerned, contact your pediatrician or healthcare provider without delay.
Do not delay emergency care if your child develops serious symptoms like breathing difficulties, chest pain, confusion, or persistent vomiting.
Maintain up-to-date vaccination and well-child checks, following your local public health guidance.

Prevention and the Role of COVID-19 Precautions

While it may not be possible to prevent Kawasaki disease outright due to its unclear etiology, preventing exposure to respiratory viruses, including COVID-19, may help reduce risk. This includes regular handwashing, mask use in high-risk settings, adhering to public health advice, and vaccination when eligible. Parents can further protect their children by ensuring prompt management of fevers and seeking medical advice if symptoms appear unusual or persistent.

FAQs: Frequently Asked Questions

Is my child at high risk for Kawasaki disease if they test positive for COVID-19?

Most children with COVID-19 have mild symptoms and do not develop Kawasaki disease or MIS-C. However, all parents should monitor for persistent fever and Kawasaki symptoms, especially after recent infection or known exposure.

Is Kawasaki disease contagious?

No. Kawasaki disease itself is not contagious, but the viral triggers (such as SARS-CoV-2) can be spread from person to person.

Can COVID-19 vaccinations prevent Kawasaki disease or MIS-C?

COVID-19 vaccines reduce the risk of severe illness and, by limiting SARS-CoV-2 infection, may indirectly reduce the risk of post-infectious complications like MIS-C in eligible children.

Are there long-term effects for children diagnosed with Kawasaki disease or MIS-C?

Most children recover fully with prompt treatment. Some may need ongoing monitoring for heart function, particularly if coronary artery involvement was noted, as rare complications can persist or recur.

What should I do if I suspect my child has Kawasaki disease?

Contact your pediatrician or healthcare provider immediately. Early diagnosis and treatment are crucial to reduce the risk of serious complications.

References

Emergence of Kawasaki disease related to SARS-CoV-2 infection in children and its association with COVID-19 epidemic surges.
Relationship and distinctions between COVID-19-related inflammatory syndromes (MIS-C) and Kawasaki disease in children.
Overview of symptoms, risks, and pediatric guidance during new COVID-19 outbreaks.
Impact of COVID-19 on course, treatment, and IVIG resistance in Kawasaki disease.

References

Author

medha deb

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb